Literature DB >> 17395979

Incidence and familial risks in pituitary adenoma and associated tumors.

Kari Hemminki1, Asta Försti, Jianguang Ji.   

Abstract

Reliable data on familial risks are important for clinical counseling and cancer genetics. We wanted to study incidence trends and familial risks for pituitary adenomas and associated tumors through parental and sibling probands, using the nation-wide Swedish Family-Cancer Database on 10.5 million individuals, containing families with parents and offspring. Cancer data were retrieved from the Swedish Cancer Registry from years 1958 to 2002, including 3239 pituitary tumor patients. Familial risk for offspring was defined through standardized incidence ratio (SIR), adjusted for many variables. The incidence of pituitary adenoma has increased moderately from 1958 to the 1990s and declined thereafter. There were only three offspring-parent pairs with a concordant pituitary tumor, the SIR was not significant. Parental skin cancer (SIR 1.60) and leukemia (1.90, chronic lymphatic leukemia 2.59) were associated with offspring pituitary adenoma diagnosed at any age up to 70 years. There was a strong association of pituitary adenomas with nervous system hemangiopericytomas, SIR 182. The only significant association among siblings was between pituitary tumors and breast cancer (1.46). The risk of pituitary adenoma was marginally increased in individuals whose siblings were diagnosed with colorectal cancer. The results suggest an association of pituitary adenomas with nervous system hemangiopericytomas and breast and colorectal cancers, in addition to some other tumor types. Whether these associations can be explained by the recently identified pituitary adenoma predisposing gene, AIP, remains to be established.

Entities:  

Mesh:

Year:  2007        PMID: 17395979     DOI: 10.1677/ERC-06-0008

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  12 in total

1.  The incidence of cerebrovascular accidents and second brain tumors in patients with pituitary adenoma: a population-based study.

Authors:  Paul D Brown; Miran Blanchard; Krishan Jethwa; Kelly D Flemming; Cerise A Brown; Robert W Kline; Debra J Jacobson; Jennifer St Sauver; Bruce E Pollock; Yolanda I Garces; Scott L Stafford; Michael J Link; Dana Erickson; Robert L Foote; Nadia N I Laack
Journal:  Neurooncol Pract       Date:  2014-03

2.  Familial Cancer Clustering in Patients with Prolactinoma.

Authors:  Sandra Pekic; Ivan Soldatovic; Dragana Miljic; Marko Stojanovic; Mirjana Doknic; Milan Petakov; Vera Popovic
Journal:  Horm Cancer       Date:  2018-09-08       Impact factor: 3.869

3.  Demographic differences in incidence for pituitary adenoma.

Authors:  Bradley D McDowell; Robert B Wallace; Ryan M Carnahan; Elizabeth A Chrischilles; Charles F Lynch; Janet A Schlechte
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

Review 4.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 5.  Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Authors:  Kevin C J Yuen; Anthony P Heaney; Vera Popovic
Journal:  Endocrine       Date:  2016-01-05       Impact factor: 3.633

6.  Should aip gene screening be recommended in family members of FIPA patients with R16H variant?

Authors:  Maria Chiara Zatelli; Maria Luisa Torre; Rachele Rossi; Marta Ragonese; Francesco Trimarchi; Ettore degli Uberti; Salvatore Cannavò
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

7.  Family history of cancer in benign brain tumor subtypes versus gliomas.

Authors:  Quinn T Ostrom; Christopher McCulloh; Yanwen Chen; Karen Devine; Yingli Wolinsky; Perica Davitkov; Sarah Robbins; Rajesh Cherukuri; Ashokkumar Patel; Rajnish Gupta; Mark Cohen; Jaime Vengoechea Barrios; Cathy Brewer; Cathy Schilero; Kathy Smolenski; Mary McGraw; Barbara Denk; Theresa Naska; Frances Laube; Ruth Steele; Dale Greene; Alison Kastl; Susan Bell; Dina Aziz; E A Chiocca; Christopher McPherson; Ronald Warnick; Gene H Barnett; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Front Oncol       Date:  2012-02-28       Impact factor: 6.244

8.  Intraoperative handheld optical coherence tomography forward-viewing probe: physical performance and preliminary animal imaging.

Authors:  Cuiru Sun; Kenneth K C Lee; Barry Vuong; Michael D Cusimano; Alexander Brukson; Antonio Mauro; Nigel Munce; Brian K Courtney; Beau A Standish; Victor X D Yang
Journal:  Biomed Opt Express       Date:  2012-05-16       Impact factor: 3.732

9.  Clinicopathologic analysis of pituitary adenoma: a single institute experience.

Authors:  Hwa Jin Cho; Hanna Kim; Yoon Jin Kwak; Jeong Wook Seo; Sun Ha Paek; Chul-Ho Sohn; Jung Min Yun; Da Seu Ran Kim; Peter Kang; Peom Park; Sung-Hye Park
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

10.  Evaluation of Clinical and Magnetic Resonance Imaging Profile of Pituitary Macroadenoma: A Prospective Study.

Authors:  Kamini Gupta; Shivam Sahni; Kavita Saggar; Gaurav Vashisht
Journal:  J Nat Sci Biol Med       Date:  2018 Jan-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.